myelodysplastic syndromes (MDS) | Page 6 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients

Author(s): 
Saeed L, Patnaik MM, Begna KH, Al-Kali A, Litzow MR, Hanson CA, Ketterling RP, Porrata LF, Pardanani A, Gangat N, Tefferi A
Primary Author: 
Saeed L
Journal Title: 
Blood Cancer J
Original Publication Date: 
Mar 2017

Current prognostic models for

Bone Marrow Diseases: 

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

Author(s): 
Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G
Primary Author: 
Daher M
Journal Title: 
Am J Hematol
Original Publication Date: 
Mar 2017

Bone Marrow Diseases: 

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Author(s): 
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME
Primary Author: 
Scott BL
Journal Title: 
J Clin Oncol
Original Publication Date: 
Apr 2017

Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC).

Bone Marrow Diseases: 

Infectious complications in patients with myelodysplastic syndromes: a review of the literature with emphasis on patients treated with 5-azacitidine

Author(s): 
Radsak M, Platzbecker U, Schmidt CS, Hofmann WK, Nolte F
Primary Author: 
Radsak M
Journal Title: 
Eur J Haematol
Original Publication Date: 
Mar 2017

Bone Marrow Diseases: 

Allogeneic Hematopoietic Stem Cell Transplantation is Underutilized in Older Patients with Myelodysplastic Syndromes

Author(s): 
Getta BM, Kishtagari A, Hilden P, Tallman MS, Maloy M, Gonzales P, Castro-Malaspina H, Perales MA, Giralt S, Tamari R, Klimek V
Primary Author: 
Getta BM
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Mar 2017

Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative treatment for myelodysplastic syndrome (MDS). The proportion of MDS patients referred for transplant evaluation, those undergoing transplantation and the reasons for not undergoing transplant are unknown. In this retrospective analysis, pre-defined HCT eligibility and indications criteria were applied to 362 unselected patients with newly diagnosed MDS seen by Leukemia faculty between 2008 and 2015 at Memorial Sloan Kettering Cancer Center.

Bone Marrow Diseases: 

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Author(s): 
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F
Primary Author: 
Park S
Journal Title: 
J Clin Oncol
Original Publication Date: 
Mar 2017

Purpose Most anemic patients with non-deleted 5q lower-risk

Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

Author(s): 
Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, DiBella N, Garcia-Manero G.
Primary Author: 
Lyons RM
Journal Title: 
Leuk Res
Original Publication Date: 
Jan 2017

Prospective data are needed to ascertain the impact of

Bone Marrow Diseases: 

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

Author(s): 
de Montalembert M, Ribeil JA, Brousse V, Guerci-Bresler A, Stamatoullas A, Vannier JP, Dumesnil C, Lahary A, Touati M, Bouabdallah K, Cavazzana M, Chauzit E, Baptiste A, Lefebvre T, Puy H, Elie C, Karim Z, Ernst O, Rose C
Primary Author: 
de Montalembert M
Journal Title: 
PLoS One
Original Publication Date: 
Mar 2017

The risk and clinical significance of cardiac

Bone Marrow Diseases: